It has taught us that Myc inhibition is a safe and effective therapeutic strategy that shares the advantages of targeted drugs—impacting more on cancer cells than their neighboring normal tissues—and at the same time overcomes their drawbacks—the emergence of resistance—by attacking a central non-redundant function in most, if not all, tumor cells. This evidence concerns the gene MYC and neoplasm.